X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Lymphir™ (denileukin diftitox) in combination with FDA-approved CAR-T products like tisagenlecleucel or lisocabtagene maraleucel is being investigated for the treatment of relapsed or refractory B-cell lymphomas.
Lead Product(s): Denileukin Diftitox,Tisagenlecleucel
Therapeutic Area: Oncology Product Name: Lymphir
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
Lymphir (denileukin diftitox) is a recombinant fusion protein that combines the interleukin-2 receptor binding domain with diphtheria toxin fragments. It is being evaluated for the treatment of adults with relapsed or refractory cutaneous t-cell lymphoma.
Lead Product(s): Denileukin Diftitox
Therapeutic Area: Oncology Product Name: Lymphir
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
The net proceeds will be used for the development of Lymphir (denileukin diftitox-cxdl, E7777), a purified reformulation of denileukin diftitox, to treat larger patient populations with additional indications in peripheral T-cell lymphoma (PTCL) and immuno-oncology.
Lead Product(s): Denileukin Diftitox
Therapeutic Area: Oncology Product Name: Lymphir
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: New Jersey Economic Development Authority
Deal Size: $2.4 million Upfront Cash: Undisclosed
Deal Type: Funding March 07, 2024
Details:
Lymphir (denileukin diftitox) is a recombinant fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments. It is being developed for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma.
Lead Product(s): Denileukin Diftitox
Therapeutic Area: Oncology Product Name: Lymphir
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
LYMPHIR (denileukin diftitox-cxdl) is a recombinant fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments.
Lead Product(s): Denileukin Diftitox-cxdl
Therapeutic Area: Oncology Product Name: Lymphir
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2023
Details:
Mino-Lok (MLT), a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
LYMPHIR (denileukin diftitox-cxdl) is a recombinant fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments.
Lead Product(s): Denileukin Diftitox-cxdl
Therapeutic Area: Oncology Product Name: Lymphir
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ajinomoto Company
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2023
Details:
CITI-002 (lidocaine-halobetasol propionate) is a proprietary topical formulation intended to provide symptomatic relief to individuals suffering from hemorrhoids, a gastrointestinal disorder characterized by pain, swelling, itching, tenderness, and bleeding.
Lead Product(s): Lidocaine,Halobetasol
Therapeutic Area: Gastroenterology Product Name: CITI-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
The net proceeds will be used to fund the company's pre-clinical and clinical development of its product candidates, including Mino-Lok® (minocycline), an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and CLABSIs.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 08, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
